Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Czechia / NCT06529978
Recruiting Not applicable

Endocardial Mapping With the CoreMap EP Mapping System

NCT06529978 · tracked via the Priya Life Science Czechia tracker
Sponsor
CoreMap Inc
Phase
Not applicable
Started
2024-07-25
Last updated
2026-07-14

Condition(s) studied

Persistent Atrial Fibrillation

Investigational drug(s) / intervention(s)

CoreMap EP Mapping System MappingCoreMap EP Mapping System Map-Guided Ablation

CoreMap EP Mapping System Mapping: Endocardial mapping to collect and analyze high fidelity endocardial EGMs in patients with persistent and long-standing persistent AF.

CoreMap EP Mapping System Map-Guided Ablation: Initial development and evaluation of a map-guided tailored ablation strategy and to demonstrate safety and chronic efficacy of the CoreMap EP Mapping System.

Study summary

This is a global, multi-site, prospective, feasibility study.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: 1. Subject has persistent or long-standing persistent AF, at the discretion of the investigator (Phase 1 \& 2) 2. Subject has PerAF with no history of prior AF ablation therapy (Phase 3) 3. Subject is 18 to 80 years of age 4. Subject has presence of AF-related symptoms and is scheduled for clinically indicated standard of care AF ablation to manage PerAF (Phase 2 or 3) or long-standing PerAF (Phase 2) 5. Subject is able to provide written informed consent 6. Subject is able and willing to complete all study procedures Exclusion Criteria: 1. Any of the following within three months of enrollment: 1. Myocardial infarction (MI) 2. Any surgical or percutaneous cardiac procedure including coronary intervention and cardiac ablation 3. Confirmed thrombus on imaging 2. Any of the following within six months of enrollment: 1. Cardiac surgery including coronary artery bypass grafting, ventriculotomy, atriotomy 2. Thromboembolic event (stroke) 3. Any of the following cardiac conditions: 1. New York Heart Association (NYHA) IV 2. Left ventricular ejection fraction (LVEF) \< 30% 3. Left atrial diameter \>55mm (anterioposterior) (Phase 3) 4. Carotid stenting or endarterectomy 5. Atrial or ventricular septal closure or left atrial appendage closure 6. Implanted permanent pacemaker, biventricular pacemaker, or any type of implantable cardiac defibrillator; loop recorders are permitted. 7. Presence of intramural thrombus, tumor (including atrial myxoma), or other abnormality that precludes vascular access, catheter introduction, or manipulation 8. Unstable angina 9. Prior mitral or tricuspid valve surgery, repair, prosthetic or mechanical valve 10. Moderate to severe mitral valve stenosis or other severe valvular disease 11. Any blood clotting or bleeding abnormalities 4. Contraindication to systemic anticoagulation 5. AF secondary to electrolyte imbalance, acute alcohol intoxication, or reversible or non-cardiac cause 6. Body mass index (BMI) \> 40 kg/m2 7. Severe pulmonary disease, pulmonary hypertension, or any chronic respiratory condition 8. Renal failure requiring dialysis or transplant 9. Acute illness, active systemic infection, or sepsis 10. Active drug or alcohol dependency 11. Hypertrophic cardiomyopathy or cardiac amyloidosis 12. Cor pulmonale 13. Any contra-indication that may extend procedure time, at the discretion of the operator 14. Any woman known to be pregnant or breastfeeding, or any woman of childbearing potential who is not on a reliable form of birth regulation method or abstinence 15. Subject considered part of vulnerable population 16. Life expectancy less than one year 17. Employee of the study site or Sponsor 18. Subjects who are currently enrolled in another study that would directly interfere with this study

Primary outcome measure(s)

Trial sites (4)

FacilityCityRegionStatus
NCH Downtown Baker Hospital Naples Florida Enrolling By Invitation
University of Vermont Medical Center Burlington Vermont Enrolling By Invitation
Virginia Commonwealth University (VCU) Richmond Virginia Enrolling By Invitation
Na Homolce Hospital Praha Klanovice Czechia Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06529978 on ClinicalTrials.gov ↗ ← All trials in Czechia